

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonapplications under 37 C.F.R. §1.53(b))

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

Attorney Docket No.

PC25375A

First Inventor

Charles Eric Mowbray

Title

PYRAZOLE DERIVATIVES

Express Mail Label No.

EL969716378US

APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.		ADDRESS TO:	
		Mail Stop Patent Applications Commissioner for Patents Box 1450 Alexandria, VA 22313-1450	
1. <input checked="" type="checkbox"/> Fee Transmittal Form (e.g., PTO/SB/17) <i>(Submit an original, and a duplicate for fee processing)</i>	7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or computer Program (Appendix)		
2. <input type="checkbox"/> Applicant claims small entity status See 37 CFR 1.27	8. Nucleotide and/or Amino Acid Sequence Submission <i>(if applicable, all necessary)</i>		
3. <input checked="" type="checkbox"/> Specification [Total Pages 28]	a. <input type="checkbox"/> Computer Readable Copy (CRF)		
(preferred arrangement set forth below) <ul style="list-style-type: none"> - Descriptive title of the Invention - Cross References to Related Applications - Statement Regarding Fed sponsored R&D - Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention - Brief Summary of the Invention - Brief Description of the Drawings (<i>if filed</i>) - Detailed Description - Claim(s) - Abstract of the Disclosure 			
4. <input type="checkbox"/> Drawing(s) (35 U.S.C. 113) [Total sheets]	b. Specification Sequence Listing on: <ul style="list-style-type: none"> i. <input type="checkbox"/> CD-ROM or CD-R (2 copies) ii. <input type="checkbox"/> Paper 		
5. <input type="checkbox"/> Oath or Declaration [Total pages]	c. <input type="checkbox"/> Statement verifying identity of above copies		
a. <input type="checkbox"/> Newly executed (original or copy) b. <input type="checkbox"/> Copy from a prior application (37 CFR §1.63(d)) <i>(for continuation/divisional with Box 18 completed)</i> <ul style="list-style-type: none"> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 			
6.. <input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76	ACCOMPANYING APPLICATION PARTS		
18. If a CONTINUING APPLICATION , check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.	9. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))		
	10. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i>		
	11. <input type="checkbox"/> English Translation Document (<i>if applicable</i>)		
	12. <input type="checkbox"/> Information Disclosure Statement (IDS)/PTO-1449 <input type="checkbox"/> Copies of IDS Citations		
	13. <input type="checkbox"/> Preliminary Amendment		
	14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>		
	15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>		
	16. <input type="checkbox"/> Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.		
	17. <input type="checkbox"/> Other:		

18. If a CONTINUING APPLICATION , check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37CFR 1.76.	
<input type="checkbox"/> Continuation	<input type="checkbox"/> Divisional
<input type="checkbox"/> Continuation-in-part (CIP)	of prior application No: _____ / _____
Prior application information: Examiner _____ Group/Art Unit: _____	

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts

19. CORRESPONDENCE ADDRESS

<input checked="" type="checkbox"/> Customer Number	28940	<input type="checkbox"/> Correspondence address below			
Name	Pfizer, Inc.				
Address	10777 Science Center Drive				
City	San Diego	State	CA	Zip Code	92121
Country	U.S.A.	Telephone	858-526-4608	Fax	858-678-8233
NAME (Print/type)	Keith D. Hutchinson	Registration No. (Attorney/Agent)	43,687		
Signature	September 12, 2003				

This collection of information is required by 37 CFR 1.53(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



17698
09/12/03

PTO/SB/17 (05-03)
Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small status. See 37 CFR 1.27

Total Amount of Payment (\$1,450.00)

METHOD OF PAYMENT (check all that apply)

Check Credit Card Money Other None
Order

Deposit Account:

Deposit
Account
Number

500329

Deposit
Account
Name

Agouron Pharmaceuticals, Inc.

The Director is authorized to: (check all that apply)

- Charge fee(s) indicated below Credit any overpayments
 Charge any additional fee(s) during the pendency of this application
 Charge fee(s) indicated below, except for the filing fee
to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Small Entity

Fee Code (\\$)	Fee 1001	Fee Code (\\$)	Fee 1001	Fee Description	Fee Paid
750	750	375	375	Utility filing fee	750
330	330	165	165	Design filing fee	
520	520	260	260	Plant filing fee	
750	750	375	375	Reissue filing fee	
160	160	80	80	filing fee	
Subtotal (1)		\$ 750			

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

	Extra Claims	Fee from below	Fee Paid
Total Claims	19 - 20 =	0 x 0 = 0	0
Independent Claims	8 - 3 =	5 x 84.00 = 420.00	420.00
Multiple Dependent		280.00 = 280.00	280.00

Large Entity Small Entity

Fee Code (\\$)	Fee 1202	Fee Code (\\$)	Fee Description
18	18	9	Claims in excess of 20
84	84	42	Independent claims in excess of 3
280	280	140	Multiple dependent claim, if not paid
84	84	42	**Reissue independent claims over original patent
18	18	9	**Reissue independent claims over original patent

SUBTOTAL (2) (\$ 700.00)

Complete if Known	
Application Number	TBA
Filing Date	Herewith
First Named Inventor	Charles Eric Mowbray
Examiner Name	TBA
Art Unit	TBA
Attorney Docket No.	PC25375A

FEE CALCULATION (continued)

3. ADDITIONAL FEES				
Large Entity	Small Entity			
Fee Code (\\$)	Fee Code (\\$)	Fee Code (\\$)	Fee Code (\\$)	Fee Description
1051	130	2051	65	Surcharge – late fee or oath
1052	50	2052	25	Surcharge–late filing fee or cover sheet
1053	130	1053	130	Non-English specification
1812	2,520	1812	2,520	For filing a request for reexamination
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action
1251	110	2251	55	Extension for reply within first month
1252	410	2252	205	Extension for reply within second month
1253	930	2253	465	Extension for reply within third month
1254	1,450	2254	725	Extension for reply within fourth month
1255	1,970	2255	985	Extension for reply within fifth month
1401	320	2401	160	Notice of Appeal
1402	320	2402	160	Filing a brief in support of an appeal
1403	280	2403	140	Request for oral hearing
1451	1,510	1451	1,510	Petition to institute a public use proceeding
1452	110	2452	55	Petition to revive unavoidable
1453	1,300	2453	650	Petition to revive – unintentional
1501	1,300	2501	650	Utility issue fee (or reissue)
1502	470	2502	235	Design issue fee
1503	630	2503	315	Plant issue fee
1460	130	1460	130	Petitions to the Commissioner
1807	50	1807	50	Petitions to the Commissioner
1806	180	1806	180	Submission of Information Disclosure Stmt
8021	40	8021	40	Recording each patent assignment per property (times number of properties)
1809	750	2809	375	Filing a submission after final rejection (37 CFR 1.129(a))
1810	750	2610	375	For each additional invention to be examined (37 CFR 1.129(b))
1801	750	2810	375	Request for Continued Examination (RCE)
1802	900	1802	900	Request for expedited examination of a design application
1802	900	1802	900	Request for expedited examination of a design application
Other Fee (specify)				

*Reduced by Basic Filing Fee Paid Subtotal (3) (\$)

(Complete if applicable)

Name (Printed/Type)	Keith D. Hutchinson	Registration No.	43,687	Telephone	858-526-4608
Signature	<i>Keith D. Hutchinson</i>				
		Date	September 12, 2003		

Warning: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.


This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 137 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-pat-9199 and select option 2.

Certificate of Mailing (37 C.F.R. §1.10);
 I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail #EL969716378US in an envelope addressed to: Mail Stop: Patent Applications, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450 on this 12th day of September 2003.

s/

Julie Agozino



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
CHARLES ERIC MOWBRAY, ET. AL.

Serial No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Filed: Herewith

For: PYRAZOLE DERIVATIVES

Mail Stop: Patent Applications
 Honorable Commissioner For Patents
 P.O. Box 1450
 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith are the following documents:

- | | | |
|----|--|---------------------|
| 1. | Application Data Sheet | 2 pages; |
| 2. | Utility Patent Application Transmittal | 1 page; |
| 3. | Fee Transmittal | 1 page + duplicate; |
| 4. | Specification | 28 pages total; and |
| | • Claims (5 pages) | |
| | • Abstract (1 page) | |
| 5. | Return Postcard. | |

Respectfully submitted,

Date: Sept. 12, 2003

Keith D. Hutchinson
 Keith D. Hutchinson
 Attorney For Applicants
 Registration No. 43,687

Agouron Pharmaceuticals, Inc./A Pfizer Company
 Patent Department
 10777 Science Center Drive
 San Diego, California 92121
 Phone: (858) 526-4608
 Fax: (858) 678-8233